Abstract
Men with BRCA2 mutations have been found to be at increased risk of developing prostate cancer. There is a recent report that BRCA2 carriers with prostate cancer have poorer survival than noncarrier prostate cancer patients. In this study, we compared survival of men with a BRCA2 mutation and prostate cancer with that of men with a BRCA1 mutation and prostate cancer. We obtained the age at diagnosis, age at death or current age from 182 men with prostate cancer from families with a BRCA2 mutation and from 119 men with prostate cancer from families with a BRCA1 mutation. The median survival from diagnosis was 4.0 years for men with a BRCA2 mutation vs 8.0 years for men with a BRCA1 mutation, and the difference was highly significant (P<0.01). It may be important to develop targeted chemotherapies to treat prostate cancer in men with a BRCA2 mutation.
Original language | English (US) |
---|---|
Pages (from-to) | 371-374 |
Number of pages | 4 |
Journal | British journal of cancer |
Volume | 99 |
Issue number | 2 |
DOIs | |
State | Published - Jul 22 2008 |
Keywords
- BRCA1
- BRCA2
- Prostate cancer
ASJC Scopus subject areas
- Oncology
- Cancer Research